Recent Updates
Recently added Catalysts
ADMA Negative Sentiment Score: 25/100

ADMA Biologics (NASDAQ: ADMA) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.

Key Takeaway: ADMA Biologics is facing scrutiny from Lowey Dannenberg P.C. regarding potential violations of federal securities laws. This follows a report by Culper Research which claims the company engaged in channel stuffing to inflate its revenue figures falsely. It is alleged that ADMA Biologics offered rebates and extended payment terms to a distributor to create an appearance of growth that did not reflect actual performance. The investigation seeks to determine whether the company's executives provided investors with accurate information.

Market Sentiment Analysis

CONCERNS & RISKS

  • ADMA Biologics is under investigation for potential violations of federal securities laws.
  • A report suggests the company engaged in channel stuffing, artificially inflating reported revenues.
  • The company's growth figures were misleading as they indicated a 20% growth instead of a potential 3% decline.

Full Press Release Details

NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a top complex litigation law firm, is investigating ADMA Biologics (NASDAQ: ADMA) (“ADMA Biologics” or the “Company”) for potential violations of the federal securities laws.
On March 24, 2026, Culper Research, an investigative research firm, published a report titled “ADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and -3% Real Growth in 2025 vs. +20% Reported.” The report revealed, among other things, that in 2025 ADMA Biologics induced one of its distributors to “stock excess ASCENIV by offering rebates and extended payment terms in order to meet order expectations.” This allegedly allowed ADMA Biologics to book revenue and “report[] growth that was never there.” According to Culper Research, had ADMA Biologics not engaged in this alleged channel stuffing scheme, it would have experienced revenue declines of 3% in 2025 instead of the reported 20% growth.
“Our investigation concerns whether the company and its executives provided investors with accurate and complete information about the company,” said attorney Andrea Farah, Lowey Dannenberg, P.C. partner and head of the firm’s securities practice.
If you suffered a loss of more than $50,000 in ADMA Biologics securities, and wish to participate, or learn more about your eligibility, click here, or contact our attorneys Andrea Farah (afarah@lowey.com) at (914)733-7256 or Vincent R. Cappucci Jr. (vcappucci@lowey.com) at (914)733-7278. To submit additional details, you can also visit our firm’s website here.
About Lowey Dannenberg
Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.
Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601

Tags

securities fraud class action

Frequently Asked Questions

What is the investigation about ADMA Biologics?

Lowey Dannenberg P.C. is investigating ADMA Biologics for potential federal securities law violations.

What report raised concerns about ADMA Biologics?

Culper Research published a report alleging channel stuffing and misleading revenue figures for ADMA Biologics.

What is 'channel stuffing' in relation to ADMA?

Channel stuffing refers to ADMA allegedly inducing a distributor to stock excess ASCENIV to inflate revenue.

Who can participate in the investigation?

Individuals who lost over $50,000 in ADMA Biologics securities may be eligible to participate.

What services does Lowey Dannenberg provide?

The firm represents investors who suffered losses due to corporate fraud and violations of securities laws.

Last updated: Apr 10, 2026